SignaBlok Reveals Promising Preclinical Data for Pancreatic Cancer Treatment
TL;DR
SignaBlok, Inc. to present positive preclinical oncology data on macrophage-restricted TREM-1 inhibitor, showcasing potential advantage in cancer treatment.
SignaBlok's TREM-1 inhibitor prevents cancer recurrence, reverses immunosuppression, and showcases new mechanism-based peptide therapies for multiple diseases.
SignaBlok's innovation in cancer treatment offers hope for improving complete response rate and survival, potentially benefiting patients with hard-to-treat solid tumors.
SignaBlok's SCHOOL technology platform highlights a novel approach to inflammation treatment, promising new insights into cancer therapy and immune signaling.
Found this article helpful?
Share it with your network and spread the knowledge!
Biotechnology researchers at SignaBlok have developed a potentially groundbreaking macrophage-restricted TREM-1 inhibitor that could revolutionize pancreatic cancer treatment. Preclinical data presented at the 2025 American Association for Cancer Research Annual Meeting suggests the drug may significantly improve patient outcomes by addressing critical challenges in cancer therapy.
The experimental studies revealed that the TREM-1 inhibitor prevents cancer recurrence and enhances survival rates when administered after standard chemotherapy. Notably, the drug demonstrated an ability to reverse immunosuppression and overcome resistance to anti-PD-L1 immunotherapy, which has been a persistent challenge in pancreatic cancer treatment.
Pancreatic cancer remains one of the most deadly malignancies, with a devastating 5-year survival rate of only 13%. The current research offers hope for patients facing this aggressive disease by targeting TREM-1, an inflammation amplifier critically involved in cancer pathogenesis.
Rodent studies indicated the drug's safety and tolerability, while also highlighting the potential of SignaBlok's proprietary SCHOOL technology platform. The company's unique approach using ligand-independent inhibitory peptides could potentially minimize failure risks associated with new therapeutic mechanisms.
The research suggests broader implications beyond pancreatic cancer, potentially offering new treatment strategies for other inflammation-associated, hard-to-treat solid tumors. By targeting TREM-1, the drug represents a novel approach to modulating the inflammatory processes that contribute to cancer progression.
Dr. Alexander B. Sigalov, the study's principal investigator, will present the detailed findings in a poster session at the AACR Annual Meeting in Chicago, providing the scientific community with insights into this promising therapeutic approach.
Curated from 24-7 Press Release
